Market OverviewThe Orphan Drugs Market is a specialized sector within the pharmaceutical industry that focuses on the ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

"We want people to think of Pfizer in a different way," says Brenna Robinson, director, Global Reputation ... thus extending further the reach of the 'Get Old' campaign's engagement.

It's a blow to the SCD community, as Oxbryta (voxelotor) was the first drug to reach ... in 2022 of Global Blood Therapeutics (GBT), which brought Oxbryta to market in 2019. Pfizer said in a ...

The discovery has shed light on a complex blood interaction that has likely always been present in humans but was unnoticed ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Introduction Therapeutic antibodies are laboratory-engineered proteins designed to replicate the immune system's natural ability to combat dise ...

Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability RBI-4000's ...

View the full release here: "As Cognito nears completion of enrollment in our pivotal HOPE trial and prepares for regulatory ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...